Drug-resistant Lung Cancer Cells Research Articles

シスプラチン誘導多剤耐性肺癌細胞株の樹立と自己リンパ球による細胞傷害性の検討

薬剤耐性における養子免疫療法の有用性を推測するため, 肺癌患者の胸水から肺小細胞癌細胞株 (STC1) と肺非小細胞癌細胞株 (LO301) およびそれらのシスプラチン耐性細胞株 (STC1/CDDP, LO301/CDDP) を樹立して, それらの細胞株に対する自己のリンパ球の細胞傷害性を比較検討した.MTT assayを用いた薬剤感受性試験では, STC1/CDDPは, CDDP, MMC, VCR, CPA, VP-16について耐性が認められ, LO301/CDDPは, CDDP, ADM, MMC, VCR, VP-16について耐性が認められた.IL-2加で培養した自己のリンパ球は, どちらも薬剤耐性細胞株に対して高い細胞傷害性を有していた.invitroのautologousな系を用いたこれらの結果から, 薬剤耐性を示した肺癌に対する養子免疫療法の有用性が示唆された.

Radiation sensitivities in various anticancer drug resistant human lung cancer cell lines and mechanism of radioresistance in cis-diamminedichloroplatinum (II) resistant lung cancer cell line

Radiation sensitivities in various anticancer drug resistant human lung cancer cell lines and mechanism of radioresistance in cis-diamminedichloroplatinum (II) resistant lung cancer cell line

Topoisomerase II alterations in the drug resistant small cell lung cancer cell line H209/V6: S.E.L. Mirski, K.C. Almquist, C.D. Evans, B.G. Campling and S.P.C. Cole. Departments of Oncology and Pharmacology, Queen's University, Kingston, Canada K7L 3N6

Topoisomerase II alterations in the drug resistant small cell lung cancer cell line H209/V6: S.E.L. Mirski, K.C. Almquist, C.D. Evans, B.G. Campling and S.P.C. Cole. Departments of Oncology and Pharmacology, Queen's University, Kingston, Canada K7L 3N6

Drug-resistant small cell lung cancer (SCLC) cells are more sensitive to lonidamine (LND), a new cytotoxic agent, than the parent cells

Drug-resistant small cell lung cancer (SCLC) cells are more sensitive to lonidamine (LND), a new cytotoxic agent, than the parent cells

Chapter 21 Expression of monoclonal antibody-defined lung tumour antigens in drug resistant lung tumour cell lines

The expression of monoclonal antibody (Moab)-defined lung tumour antigens has been investigated in in vitro-derived multidrug-resistant (MDR) variants of small cell (SCLC) and non-small cell (NSCLC) lung tumour cell lines. The majority of Moabs tested reacted equally well with MDR and drug-sensitive SCLC and NSCLC cells. However, in contrast to drug sensitive SCLC cells, MDR-SCLC cells failed to express the glycolipid antigen defined by Moab LCA1/LC38, showed increased expression of 2 glycoproteins, defined by Moabs LAM8 and SWA 4, and increased expression of the sugar epitope defined by Moab MOv15. Drug resistant large cell lung cancer cells also showed increased expression of the glycoprotein defined by Moab SWA 4 compared to the parent line which failed to react with this Moab. No significant differences were observed in the expression of lung tumour antigens by drug sensitive and resistant adenocarcinoma cells.